In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

A study by LV Prasad Eye Institute highlights rising antimicrobial resistance in post-cataract infections, with aggressive ...

Meta shares are showing early signs of technical stress after failing to extend recent highs, with price pulling back toward ...

Engineers at the University of California San Diego have developed a spray-on polymer coating that could help plants resist ...

Ceramic resonators offer an attractive alternative to quartz crystals for stabilizing oscillation frequencies in many ...

XRP sentiment has moved back into negative territory as price trades near recent lows, according to Santiment social data and long-term technical charts on X. T ...

Negative self-talk, surprisingly, can sharpen focus and drive. However, it’s only beneficial when it leads to self-correction ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

IT’S the most, wonderful time of the year… with treats aplenty and festive indulgence in full flow. And while you might feel ...

Nifty 50 is trading lower. It is currently trading flat at 26,135. The index has been coming down over the last few days.

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...

The Nifty Bank index, on the other hand, has been stable and range-bound over the last couple of weeks. Bias remains positive ...